{"count": 5, "results": [{"_id": "28460629", "pmid": 28460629, "pmcid": "PMC5412040", "title": "Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection", "journal": "BMC Nephrol", "authors": ["Reith C", "Staplin N", "Herrington WG", "Stevens W", "Emberson J", "Haynes R", "Mafham M", "Armitage J", "Cass A", "Craig JC", "Jiang L", "Pedersen T", "Baigent C", "Landray MJ", "SHARP Collaborative Group"], "date": "2017-05-01T00:00:00Z", "doi": "10.1186/s12882-017-0545-2", "meta_date_publication": "2017 May 1", "meta_volume": "18", "meta_issue": "1", "meta_pages": "147", "score": 50092.49, "text_hl": "In SHARP, @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@simvastatin/ezetimibe@@@ resulted in a significant reduction in MAEs amongst participants with moderate to advanced @<m>DISEASE_Renal_Insufficiency_Chronic</m> @DISEASE_MESH:D051436 @@@CKD@@@, with no excess risk of any of the prespecified safety outcomes. ", "citations": {"NLM": "Reith C, Staplin N, Herrington WG, Stevens W, Emberson J, Haynes R, Mafham M, Armitage J, Cass A, Craig JC, Jiang L, Pedersen T, Baigent C, Landray MJ, SHARP Collaborative Group. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection BMC Nephrol. 2017 May 1;18(1):147. PMID: 28460629", "BibTeX": "@article{28460629, title={Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection}, author={Reith C and Staplin N and Herrington WG and Stevens W and Emberson J and Haynes R and Mafham M and Armitage J and Cass A and Craig JC and Jiang L and Pedersen T and Baigent C and Landray MJ and SHARP Collaborative Group}, journal={BMC Nephrol}, volume={18}, number={1}, pages={147}}"}}, {"_id": "24720535", "pmid": 24720535, "title": "Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease.", "journal": "Eur J Clin Invest", "authors": ["Almquist T", "Jacobson SH", "Mobarrez F", "Näsman P", "Hjemdahl P"], "date": "2014-01-01T00:00:00Z", "doi": "10.1111/eci.12230", "meta_date_publication": "2014", "meta_volume": "44", "meta_issue": "3", "meta_pages": "276-84", "score": 50059.656, "text_hl": "LLT with @CHEMICAL_Sulfur @CHEMICAL_MESH:D013455 @@@S@@@ and @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@S+E@@@ reduced @GENE_CCL2 @GENE_6347 @@@MCP-1@@@ levels (P < 0 01 by anova) and @GENE_IFNG @GENE_3458 @@@IFNgamma@@@ levels (P < 0 01) in @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@DM@@@-@<m>DISEASE_Renal_Insufficiency_Chronic</m> @DISEASE_MESH:D051436 @@@CKD@@@ @SPECIES_9606 @@@patients@@@ but not in @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@DM@@@-only @SPECIES_9606 @@@patients@@@. ", "citations": {"NLM": "Almquist T, Jacobson SH, Mobarrez F, Näsman P, Hjemdahl P. Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease. Eur J Clin Invest. 2014;44(3):276-84. PMID: 24720535", "BibTeX": "@article{24720535, title={Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease.}, author={Almquist T and Jacobson SH and Mobarrez F and Näsman P and Hjemdahl P}, journal={Eur J Clin Invest}, volume={44}, number={3}, pages={276-84}}"}}, {"_id": "25887677", "pmid": 25887677, "title": "LDL-cholesterol lowering and renal outcomes.", "journal": "Curr Opin Lipidol", "authors": ["Waters DD"], "date": "2015-06-01T00:00:00Z", "doi": "10.1097/MOL.0000000000000176", "meta_date_publication": "2015 Jun", "meta_volume": "26", "meta_issue": "3", "meta_pages": "195-9", "score": 50054.34, "text_hl": "One large trial demonstrated that @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@simvastatin/ezetimibe@@@ reduced cardiovascular events in a broad spectrum of @<m>DISEASE_Renal_Insufficiency_Chronic</m> @DISEASE_MESH:D051436 @@@CKD@@@ @SPECIES_9606 @@@patients@@@. ", "citations": {"NLM": "Waters DD. LDL-cholesterol lowering and renal outcomes. Curr Opin Lipidol. 2015 Jun;26(3):195-9. PMID: 25887677", "BibTeX": "@article{25887677, title={LDL-cholesterol lowering and renal outcomes.}, author={Waters DD}, journal={Curr Opin Lipidol}, volume={26}, number={3}, pages={195-9}}"}}, {"_id": "25736071", "pmid": 25736071, "title": "Simultaneous determination of aromatic amino acids in human blood plasma by capillary electrophoresis with UV-absorption detection.", "journal": "J Sep Sci", "authors": ["Forteschi M", "Sotgia S", "Assaretti S", "Arru D", "Cambedda D", "Sotgiu E", "Zinellu A", "Carru C"], "date": "2015-05-01T00:00:00Z", "doi": "10.1002/jssc.201500038", "meta_date_publication": "2015 May", "meta_volume": "38", "meta_issue": "10", "meta_pages": "1794-9", "score": 50046.543, "text_hl": "The method suitability was tested measuring @CHEMICAL_Amino_Acids_Aromatic @CHEMICAL_MESH:D024322 @@@aromatic amino acids@@@ level in 20 @<m>DISEASE_Renal_Insufficiency_Chronic</m> @DISEASE_MESH:D051436 @@@chronic kidney disease@@@ @SPECIES_9606 @@@patients@@@ at basal level and after @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@simvastatin/ezetimibe@@@ treatment. ", "citations": {"NLM": "Forteschi M, Sotgia S, Assaretti S, Arru D, Cambedda D, Sotgiu E, Zinellu A, Carru C. Simultaneous determination of aromatic amino acids in human blood plasma by capillary electrophoresis with UV-absorption detection. J Sep Sci. 2015 May;38(10):1794-9. PMID: 25736071", "BibTeX": "@article{25736071, title={Simultaneous determination of aromatic amino acids in human blood plasma by capillary electrophoresis with UV-absorption detection.}, author={Forteschi M and Sotgia S and Assaretti S and Arru D and Cambedda D and Sotgiu E and Zinellu A and Carru C}, journal={J Sep Sci}, volume={38}, number={10}, pages={1794-9}}"}}, {"_id": "28437620", "pmid": 28437620, "title": "AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.", "journal": "Endocr Pract", "authors": ["Jellinger PS", "Handelsman Y", "Rosenblit PD", "Bloomgarden ZT", "Fonseca VA", "Garber AJ", "Grunberger G", "Guerin CK", "Bell DSH", "Mechanick JI", "Pessah-Pollack R", "Wyne K", "Smith D", "Brinton EA", "Fazio S", "Davidson M"], "date": "2017-04-01T00:00:00Z", "doi": "10.4158/EP171764.APPGL", "meta_date_publication": "2017 Apr", "meta_volume": "23", "meta_issue": "Suppl 2", "meta_pages": "1-87", "score": 50020.008, "text_hl": "ABBREVIATIONS: 4S = Scandinavian @CHEMICAL_Simvastatin @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ Survival Study @VARIANT_c.1A>C_SPTB_human @VARIANT_tmVar:c|SUB|A|1|C;HGVS:c.1A>C;VariantGroup:0;CorrespondingGene:6710;CorrespondingSpecies:9606 @@@A1C@@@ = glycated hemoglobin AACE = American Association of Clinical Endocrinologists AAP = American Academy of Pediatrics ACC = American College of Cardiology ACE = American College of Endocrinology ACS = @DISEASE_Acute_Coronary_Syndrome @DISEASE_MESH:D054058 @@@acute coronary syndrome@@@ ADMIT = @DISEASE_Cerebral_Arterial_Diseases @DISEASE_MESH:D002539 @@@Arterial Disease@@@ Multiple Intervention Trial ADVENT = Assessment of @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@ Control and Evaluation of the Efficacy of Niaspan Trial AFCAPS/TexCAPS = Air Force/Texas @DISEASE_Coronary_Artery_Disease @DISEASE_MESH:D003324 @@@Coronary Atherosclerosis@@@ Prevention Study AHA = American Heart Association AHRQ = Agency for Healthcare Research and Quality AIM-HIGH = Atherothrombosis Intervention in @DISEASE_Metabolic_Syndrome @DISEASE_MESH:D024821 @@@Metabolic Syndrome@@@ With Low HDL/High @CHEMICAL_Triglycerides @CHEMICAL_MESH:D014280 @@@Triglycerides@@@ trial ASCVD = @DISEASE_Atherosclerosis @DISEASE_MESH:D050197 @@@atherosclerotic cardiovascular disease@@@ ATP = Adult Treatment Panel apo = apolipoprotein BEL = best evidence level BIP = @CHEMICAL_Bezafibrate @CHEMICAL_MESH:D001629 @@@Bezafibrate@@@ Infarction Prevention trial BMI = body mass index CABG = coronary artery bypass graft CAC = @DISEASE_Coronary_Artery_Disease @DISEASE_MESH:D003324 @@@coronary artery calcification@@@ CARDS = Collaborative @CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@Atorvastatin@@@ @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@ Study CDP = Coronary Drug Project trial CI = confidence interval CIMT = carotid intimal media thickness @DISEASE_Chronic_Kidney_Disease_Mineral_and_Bone_Disorder @DISEASE_MESH:D012080 @@@CKD@@@ = @<m>DISEASE_Renal_Insufficiency_Chronic</m> @DISEASE_MESH:D051436 @@@chronic kidney disease@@@ CPG(s) = clinical practice guideline(s) CRP = @GENE_CRP @GENE_1401 @@@C-reactive protein@@@ CTT = @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@Cholesterol@@@ Treatment Trialists CV = cerebrovascular CVA = cerebrovascular accident EL = evidence level FH = @DISEASE_Hyperlipoproteinemia_Type_II @DISEASE_MESH:D006938 @@@familial hypercholesterolemia@@@ FIELD = Secondary Endpoints from the Fenofibrate Intervention and Event Lowering in @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@ trial FOURIER = Further Cardiovascular Outcomes Research with @GENE_PCSK9 @GENE_255738 @@@PCSK9@@@ Inhibition in Subjects With Elevated Risk trial HATS = HDL-@DISEASE_Atherosclerosis @DISEASE_MESH:D050197 @@@Atherosclerosis@@@ Treatment Study HDL-C = high-density lipoprotein @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@cholesterol@@@ HeFH = heterozygous @DISEASE_Hyperlipoproteinemia_Type_II @DISEASE_MESH:D006938 @@@familial hypercholesterolemia@@@ HHS = Helsinki Heart Study @SPECIES_11676 @@@HIV@@@ = @SPECIES_12721 @@@human immunodeficiency virus@@@ HoFH = homozygous @DISEASE_Hyperlipoproteinemia_Type_II @DISEASE_MESH:D006938 @@@familial hypercholesterolemia@@@ HPS = Heart Protection Study HPS2-THRIVE = Treatment of HDL to Reduce the Incidence of Vascular Events trial HR = hazard ratio HRT = hormone replacement therapy hsCRP = high-sensitivity CRP IMPROVE-IT = Improved Reduction of Outcomes: @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@Vytorin@@@ Efficacy International Trial IRAS = @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@Insulin Resistance Atherosclerosis@@@ Study JUPITER = Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating @CHEMICAL_Rosuvastatin_Calcium @CHEMICAL_MESH:D000068718 @@@Rosuvastatin@@@ LDL-C = low-density lipoprotein cholesterol Lp-PLA2 = lipoprotein-associated phospholipase A2 MACE = major cardiovascular events MESA = Multi-Ethnic Study of @DISEASE_Atherosclerosis @DISEASE_MESH:D050197 @@@Atherosclerosis@@@ MetS = @DISEASE_Metabolic_Syndrome @DISEASE_MESH:D024821 @@@metabolic syndrome@@@ MI = @DISEASE_Myocardial_Infarction @DISEASE_MESH:D009203 @@@myocardial infarction@@@ MRFIT = Multiple Risk Factor Intervention Trial NCEP = National @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@Cholesterol@@@ Education Program NHLBI = National Heart, Lung, and Blood Institute @DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@PCOS@@@ = @DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@polycystic ovary syndrome@@@ @GENE_PCSK9 @GENE_255738 @@@PCSK9@@@ = @GENE_PCSK9 @GENE_255738 @@@proprotein convertase subtilisin/kexin type 9@@@ Post CABG = Post Coronary Artery Bypass Graft trial PROSPER = Prospective Study of @CHEMICAL_Pravastatin @CHEMICAL_MESH:D017035 @@@Pravastatin@@@ in the Elderly at Risk trial QALY = quality-adjusted life-year ROC = receiver-operator characteristic SOC = standard of care SHARP = Study of Heart and Renal Protection T1DM = type 1 @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ mellitus T2DM = type 2 @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ mellitus TG = @CHEMICAL_Triglycerides @CHEMICAL_MESH:D014280 @@@triglycerides@@@ TNT = Treating to New Targets trial VA-HIT = Veterans Affairs High-Density Lipoprotein @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@Cholesterol@@@ Intervention Trial VLDL-C = very low-density lipoprotein cholesterol WHI = @SPECIES_9606 @@@Women@@@'s Health Initiative.", "citations": {"NLM": "Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017 Apr;23(Suppl 2):1-87. PMID: 28437620", "BibTeX": "@article{28437620, title={AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.}, author={Jellinger PS and Handelsman Y and Rosenblit PD and Bloomgarden ZT and Fonseca VA and Garber AJ and Grunberger G and Guerin CK and Bell DSH and Mechanick JI and Pessah-Pollack R and Wyne K and Smith D and Brinton EA and Fazio S and Davidson M}, journal={Endocr Pract}, volume={23}, number={Suppl 2}, pages={1-87}}"}}]}